Document:

Agreement

                                                                                 
	 

 

between

 

Zentralstelle
für private Überspielungsrechte (ZPÜ)

Gesellschaft des bürgerlichen Rechts,

and its members

 

and

 

TME
GmbH

 

Imation
Europe B.V.

 

GlassBridge
Enterprises, Inc. (formerly: Imation, Corp.)

 

    	 

    	 

    

 

 

Agreement

 

between

 

	(1)	Zentralstelle
    für private Überspielungsrechte (ZPÜ) Gesellschaft des bürgerlichen Rechts, with business address
    at Rosenheimer Str. 11, 81667 München, represented by its member GEMA – Gesellschaft für musikalische Aufführungs-
    und mechanische Vervielfältigungsrechte which is representeded by its Members of the Board Dr. Harald Heker, Georg Oeller
    and Lorenzo Colombini (“ZPÜ”),

 

acting
on its own behalf and on behalf of its members

 

GEMA
– Gesellschaft für musikalische Aufführungs- und mechanische Vervielfältigungsrechte with registered
business address at Bayreuther Straße 37-38, 10787 Berlin (“GEMA”);

 

GVL
– Gesellschaft zur Verwertung von Leistungsschutzrechte mbH with registered business address at Podbielskiallee
64, 14195 Berlin (“GVL”);

 

GÜFA
– Gesellschaft zur Übernahme und Wahrnehmung von Filmaufführungsrechten mbH with registered business address
at Vautierstraße 72, 40235 Düsseldorf (“GÜFA”);

 

GWFF
– Gesellschaft zur Wahrnehmung von Film- und Fernsehrechten mbH with registered business address at Marstallstraße
8, 80539 Munich (“GWFF”);

 

VFF
– Verwertungsgesellschaft der Film- und Fernsehproduzenten mbH with registered business address at Brienner Straße
26, 80333 Munich (“VFF”);

 

VGF
– Verwertungsgesellschaft für Nutzungsrechte an Filmwerken mbH with registered business address at Beichstraße
8, 80802 Munich (“VGF”);

 

VG
BILD-KUNST – Verwertungsgesellschaft Bild-Kunst with registered business address at Weberstraße 61, 53113 Bonn
(“VG BILD-KUNST”);

 

VG
WORT – Verwertungsgesellschaft WORT with registered business address at Untere Weidenstraße 5, 81543 Munich
(“VG WORT”);

 

TWF
– Treuhandgesellschaft Werbefilm mbH with registered business address at Thomas-Wimmer-Ring 9, 80539 Munich (“TWF”);

 

(collectively
“Collecting Societies”)

 

and

 

	(2)	TME
    GmbH with business address Mainzer Landstraße 46, 60235 Frankfurt, represented by its Director Danny Zheng (“TME”);

 

    	2/10

    	 

    

 

 

 

	(3)	Imation
    Europe B.V. with business address at GlassBridge Enterprises, Inc., 1099 Helmo Ave North # 250, Oakdale, Minnesota 55128,
    USA, represented by Danny Zheng (“Imation Europe”);
	 	 
	(4)	GlassBridge
    Enterprises, Inc. (formerly: Imation, Corp.) with business address 1099 Helmo Ave North # 250, Oakdale, Minnesota 55128,
    USA, represented by its Chief Executive Officer Danny Zheng (“GlassBridge”)

 

(TME,
Imation Europe and GlassBridge collectively: “Imation”)

 

Preamble

 

	(A)	This
    agreement applies to all companies of the Imation / GlassBridge group which ultimately has the same parent company GlassBridge
    Enterprises, Inc. and any future successors in interest or assignees of the same (collectively the “Imation Group”)
    as well as customers of the Imation Group.
	 	 
	(B)	TME,
    Imation Europe and other members of the Imation Group have distributed various analogue and digital storage media (CDs, DVDs,
    BluRay, floppy discs, audio tapes, video tapes, camcorder tapes, DAT tapes, data cartridges, flash cards) and devices (flash
    drives, solid state drives and hard disk drives) under the brand names “Imation”, “Exabyte”, “IBM”,
    “StorageTek”, “HP”, “Memorex”, “TDK”, “XtremeMac, “SUN”
    and “Nexsan” in Germany (the “Imation Products”). The members of the Imation Group have ended
    their German business by the end of 2015.
	 	 
	(C)	From
    1 January 2003 to 30 June 2008, Imation Deutschland GmbH (which was merged to TME at the end of 2010) imported and distributed
    Imation Products into and within Germany. Imation Deutschland GmbH organized its distribution activities into two separate
    distribution channels: commercial end customers were serviced via the commercial distribution channel (“Commercial
    Channel”) and private end customers were serviced via the consumer distribution channel (“Consumer Channel”).
    Imation Deutschland GmbH has paid a total of EUR 11,819,331.00 in copyright levies to ZPÜ in the period from 1 January
    2003 to 30 June 2008. This total amount includes an amount of EUR 4,481,500.00 which Imation Deutschland GmbH paid exclusively
    as levies on the sales in the Commercial Channel and which was claimed back by TME from ZPÜ in arbitration proceedings
    before the Arbitration Board according to the Act on the Protection of Copyright and Neighbouring Rights (“Arbitration
    Board”) with request filed on 30 December 2013 (case no. Sch-Urh 61/13). ZPÜ denies such separation and allocation
    of payments. The Arbitration Board has proposed that ZPÜ shall pay, by way of compromise, EUR 2.52 Mio to TME on 27 February
    2017. TME and ZPÜ have both opposed against the Arbitration Board’s decision. Currently, court proceedings are
    pending before the Higher Regional Court of Munich (case no. 6 Sch 12/17 WG) where TME requests reimbursement of EUR 4,481,500.00
    plus interests in the amount of 5% p.a. above the base interest rate (i.e., as of 29 May 2018, a total of EUR 5,298,602.09)
    against ZPÜ (the “Reimbursement Action”).

 

    	3/10

    	 

    

 

 

 

	(D)	There
    is an additional court proceeding pending between ZPÜ and TME before the Higher Regional Court of Munich (case no. 6
    Sch 27/15 WG) where ZPÜ asserts a claim for reporting on sold hard disk drives (the “Reporting Action”).
	 	 
	(E)	ZPÜ
    has invoiced copyright levies for Imation Products directly to customers of the Imation Group. Furthermore there are arbitration
    proceedings pending before the Arbitration Board between ZPÜ and customers of the Imation Group where ZPÜ asserts
    claims for copyright levies against real,- SB Warenhaus GmbH (case no. Sch-Urh 147/14), Euronics Deutschland GmbH (case no.
    Sch-Urh 116/14), ElectronicPartner Handel SE (case nos. Sch-Urh 112/15, Sch-Urh 132/16 and Sch-Urh 133/16) and Müller
    Großhandels Ltd. & Co. KG (case no. Sch-Urh 160/16) (collectively: the “Customer Arbitration Proceedings”).
    On 8 February 2018, the Arbitration Board has provided its settlement proposal in further proceedings (case no. Sch-Urh 149/14)
    between ZPÜ and Euronics Deutschland GmbH whereas Euronics Deutschland GmbH has filed an objection against this settlement
    proposal on 22 March 2018.
	 	 
	(F)	There
    are currently no court proceedings pending between ZPÜ and customers of the Imation Group with regard to copyright levies
    for Imation Products, apart from the proceedings between ZPÜ and Euronics Deutschland GmbH before the Higher Regional
    Court of Munich (case no. 6 Sch 21/18 WG), resulting from the objection of Euronics Deutschland GmbH against the settlement
    proposal in the aforementioned proceedings case no. Sch-Urh 149/14.
	 	 
	(G)	The
    Collecting Societies and Imation have reached an amicable settlement agreement in order to resolve all pending and potential
    disputes regarding payment and reimbursement of copyright levies for Imation Products.

 

Therefore,
the Collecting Societies and Imation (together the “Parties”, each a “Party”) agree as follows
(the “Agreement”):

 

	1.	Pending
    Reimbursement Action
	 	 
	1.1	The
    Parties agree to terminate the Reimbursement Action before the Higher Regional Court of Munich (case no. 6 Sch 12/17 WG) by
    filing submissions by means of which (i) the proceeding is jointly declared fully completed (“übereinstimmende
    Erledigungserklärung”) and (ii) the Higher Regional Court of Munich is advised of the cost rule set forth in
    Section 1.2 of this Agreement.
	 	 
	1.2	TME
    and ZPÜ shall each bear 50 % of the court fees and each Party shall bear its own costs and expenses with regard to the
    Reimbursement Action, including, without limitation attorney fees and travel and translation expenses. The Parties hereby
    agree to refrain from filing any motions for cost reimbursement with regard to the Reimbursement Action.
	 	 
	1.3	TME
    shall use its best efforts to file the submission pursuant to Section 1.1 within 5 Business Days (i.e., days that are not
    (i) a Saturday, (ii) a Sunday, (iii) any other day on which commer-cial banks in Germany, or the USA are required by applicable
    Laws to be closed, or (iv) any 24 or 31 December. after signature of this agreement by all Parties, a “Business Day”).
    ZPÜ shall use its best efforts to file the submission pursuant to Section 1.1 within 5 Business Days after receipt of
    the scan of the signed execution copy of this Agreement. 

 

    	4/10

    	 

    

 

 

 

	2.	Pending
    Reporting Action
	 	 
	2.1	The
    Parties agree to terminate the Reporting Action before the Higher Regional Court of Munich (case no. 6 Sch 27/15 WG) by filing
    submissions by means of which (i) the proceeding is jointly declared fully completed (“übereinstimmende Erledigungserklärung”)
    and (ii) the Higher Regional Court of Munich is advised of the cost rule set forth in Section 2.2 of this Agreement.
	 	 
	2.2	TME
    and ZPÜ shall each bear 50 % of the court fees and each Party shall bear its own costs and expenses with regard to the
    Reporting Action, including, without limitation attorney fees and travel and translation expenses. The Parties hereby agree
    to refrain from filing any motions for cost reimbursement with regard to the Reporting Action.
	 	 
	2.3	ZPÜ
    shall use its best efforts to file the submission pursuant to Section 1.1 within 5 Business Days after receipt of the scan
    of the signed execution copy of this Agreement. TME shall use its best efforts to file the submission pursuant to Section
    1.1 within 5 Business Days after receipt of a scan of the submission filed by ZPÜ pursuant to the preceding sentence.
	 	 
	3.	Pending
    Customer Arbitration Proceedings and Court Proceedings
	 	 
	3.1	ZPÜ
    agrees to use its best efforts to withdraw the Customer Arbitration Proceedings pending before the Arbitration Board (case
    nos. Sch-Urh 147/14, Sch-Urh 116/14, Sch-Urh 112/15, Sch-Urh 132/16, Sch-Urh 133/16 and Sch-Urh 160/16) and the court proceedings
    pending before the Higher Regional Court of Munich case no. 6 Sch 21/18 WG within 5 Business Days after receipt of the scan
    of the signed execution copy of this Agreement.
	 	 
	3.2	ZPÜ
    and Imation shall each bear 50 % of the board / court fees of each of the Customer Arbitration Proceedings and the court proceeding
    case no. 6 Sch 21/18 WG. Each Party shall bear its own costs and expenses with regard to the Customer Arbitration Proceedings
    and the court proceedings case no. 6 Sch 21/18 WG, including, without limitation attorney fees and travel and translation
    expenses. ZPÜ hereby agrees to refrain from filing motions for cost reimbursement with the Arbitration Board and with
    the Higher Regional Court of Munich with regard to the Customer Arbitration / Court Proceedings. Imation shall see to it (steht
    dafür ein) and procure (sorgt für) that the respective customer who is party to the Customer Arbitration
    / Court Proceedings will not request cost reimbursement from ZPÜ.

 

    	5/10

    	 

    

 

 

 

	4.	Settlement
    Payment
	 	 
	4.1	Imation
    shall make a final lump sum payment of EUR 150,000.00 by way of a bank transfer to ZPÜ’s bank account: 

 

Commerzbank
München

IBAN:
DE83 7008 0000 0387 9100 00

Swift/BIC:
DRES DE FF 700

 

	4.2	Imation
    shall make the payment pursuant to Section 4.2 without undue delay after receipt of the signed execution hardcopy of this
    Agreement and release of restricted cash at Imation’s bank (which will be released after confirmation by the relevant
    customer), at the latest by 31 January 2019.
	 	 
	5.	Waiver
    of claims by Imation
	 	 
	5.1	Provided
    that ZPÜ fully complies with its duties under this Agreement, Imation irrevocably waives and abandons any and all claims,
    demands, and causes of action, known or unknown, existing now or in the future, against the Collecting Societies for reimbursement
    of copyright levies for Imation Products, whether already invoiced by ZPÜ or not, whether already paid by Imation or
    its customers or not.
	 	 
	6.	Waiver
    of claims by Collecting Societies
	 	 
	6.1	Provided
    that Imation fully complies with its duties under this Agreement, ZPÜ on its own behalf and on behalf of its members,
    irrevocably waives and abandons any and all claims, demands, and causes of action, known or unknown, existing now or in the
    future, against Imation and the Customers (as defined in section 6.4) of the Imation Group, arising out of or relating to
    copyright levies for the Imation Products imported and/or distributed to/within the territory of Germany by Imation and procured
    by the Customers, each between 1 January 2003 and 31 December 2015, whether already invoiced by ZPÜ or not.
	 	 
	6.2	ZPÜ
    shall see to it (steht dafür ein) and procure (sorgt für) that any of its members also waive and abandon
    any and all claims, demands, and causes of action known or unknown, existing now or in the future, against Imation and the
    Customers (as defined in section 6.4) of the Imation Group, arising out of or relating to copyright levies for the Imation
    Products imported and/or distributed to/within the territory of Germany by Imation and procured by the Customers, each between
    1 January 2003 and 31 December 2015, whether already invoiced by ZPÜ or not and hereby agrees undertake to indemnify
    Imation Europe (and its affiliates) from any such claim, demand and cause of action.
	 	 
	6.3	Sections
    6.1 and 6.2 shall apply and operate as agreements for the benefit of third parties within the meaning of Section 328 (1) of
    the German Civil Code (BGB) (echter Vertrag zugunsten Dritter) for a Customer whereas such Customer is not entitled
    to claim reimbursement of copyright levies already paid for Imation Products imported and/or distributed to/within the territory
    of Germany by Imation and procured by the respective Customer, each between 1 January 2003 and 31 December 2015, against ZPÜ
    and/or any of its members except for any reimbursement of copyright levies based on an adjustment of levy rates in tariffs
    and/or collective agreements.

 

    	6/10

    	 

    

 

 

 

	6.4	A
    list of companies (the “Customers”) who have procured Imation Products from an Imation Group company, directly
    or via resellers and/or distributors, is attached as Appendix to this Agreement. Customers within the meaning of this
    Agreement also include (i) group entities of the respective Customer that may have purchased, imported or distributed Imation
    Products instead of the respective named Customer (e.g., where one Customer purchased Imation Products and a group company
    of this Customer has distributed these Imation Products in Germany), and/or (ii) group entities of the respective Customer
    that have succeeded or have been succeeded by the Customers listed in the Appendix. Where the Appendix refers to a non-German
    entity, the Agreement only applies to activities of such Customer that have been carried out in Germany.
	 	 
	7.	Miscellaneous
	 	 
	7.1	This
    Agreement represents a settlement and compromise. The Parties agree that this Agreement fully and comprehensively settles
    any disputes with regard to copyright levies for the Imation Products imported and/or distributed to/within the territory
    of Germany by Imation between 1 January 2003 and 31 December 2015.
	 	 
	7.2	Nothing
    in this Agreement shall be construed as evidence of, or any admission of, any liability or omission of any kind or as acknowledgement
    of any legal opinion or any levy rates as adequate or inadequate by any Party.
	 	 
	7.3	The
    Parties shall keep the content of this Agreement confidential. The Parties may, however, disclose this Agreement (i) if legally
    required to do so, (ii) to Collecting Societies, (iii) to customers of the Imation Group, and (iv) to a competent authority
    to the extent necessary to enforce their rights under this Agreement. Also, the Parties may disclose that the disputes regarding
    copyright levies for Imation Products were settled without disclosing details of this settlement.
	 	 
	7.4	This
    Agreement contains the full understanding and the complete and exclusive statements of the terms and conditions of the Parties’
    agreements with respect to the subject matter hereof and supersedes any prior oral or written agreements and understandings
    between the Parties with respect thereto.
	 	 
	7.5	Any
    provision of this Agreement may be amended or waived only if such amendment or waiver is effected in writing and explicitly
    refers to this Agreement. This requirement also applies to any amendment or waiver of this Section 7.5 itself.
	 	 
	7.6	This
    Agreement shall be governed by and construed in accordance with the laws of Germany and excluding any conflict-of-law rules.
    The courts of Munich shall have exclusive jurisdiction to settle any disputes or claims arising under or in connection with
    this Agreement, including its validity and termination.

    	7/10

    	 

    

 

 

 

Signatures

 

	Zentralstelle
    für private Überspielungsrechte (ZPÜ) Gesellschaft des bürgerlichen Rechts:

 

	Date:		 	Date:	
	 		 	 	
	Name:	 	 	Name:	 
	Position:	 	 	Position:	 

 

	TME
    GmbH	 	Imation
    Europe B.V.
	 	 	 
	Date:		 	Date:	
	 	 	 	 	 
	 		 	 	
	Name:	Danny
    Zheng	 	Name:	Danny
    Zheng
	Position:	Director	 	Position:	Representative

 

	GlassBridge
    Enterprises, Inc.
	 
	Date:		 	 	 
	 		 	 	 
	 	 	 	 	 
	Name:	Danny
    Zheng	 	 	 
	Position:	Director	 	 	 

 

    	8/10

    	 

    

 

 

 

	 	 

                                                                                                                                      Appendix

         

        (Customers)

         
	 

 

	Actebis
    Peacock GmbH	 	CDA
    Datentrager Albrechts GmbH	 	EXTRA
    Objekgesellschaft mbH & Co KG
	Actidata
    GmbH	 	Citti
    Markt GmbH & Co KG	 	Famila
    Handelsbetriebe GmbH
	ADVEO
    Deutschland GmbH	 	Cl.
    Bergmann GmbH & Co. KG	 	Famila
    Handelsmarkt
	Aldi
    GmbH & Co KG	 	Computerwelt	 	Fiege
    Deutschland Stiftung & Co KG
	Alexander
    Buerkle GmbH & Co KG	 	Conrad
    Electronic SE	 	Freecom
    Technologies GmbH
	ALKA
    GmbH & Co KG	 	COOP
    Eingetragene Genossenschaft	 	Friedrich
    Streb
	ALSO
    Deutschland GmbH	 	Copymedia
    Dienstleistungs- und Maschinenvertriebs GmbH	 	Funkstrom
    Grosshandels GmbH
	Amazon
    EU Sarl	 	Copytec
    Mast Kassettendienst	 	Futura
    Media Service GmbH & Co
	Angelika
    Breinbauer	 	COS
    Distributions GmbH	 	Gaefgen
    Elektrogrosshandel GmbH
	Anton
    Schlecker	 	CPI
    Computer Partner Handels GmbH	 	Galeria
    Kaufhof GmbH
	Aqipa
    GmbH	 	Despec
    Supplies GmbH	 	Georg
    Josef Kaes GmbH & Co
	Arlt
    Computer Produkte GmbH	 	Dexxon
    Data Media and Storage GmbH	 	Heix
    GmbH & Co. KG
	AV
    Com GmbH	 	Diagramm
    Halbach GmbH & Co KG	 	Hillmann
    & Ploog GmbH & Co KG
	B
    Com Computer AG	 	Digigear
    Inc	 	Home
    Video Produktion
	BDT
    Media Automation GmbH	 	DK
    Data Nordic OU	 	INCOM
    Storage GmbH
	Bonn
    Tatje Fackiner	 	Duttenhofer
    GmbH & Co. KG	 	Johann
    Fouquet GmbH
	Brommelhaupt
    Grosshandels GmbH	 	E
    Neumerkel EK	 	Kaisers
    Tengelmann AG
	Buenting Handel Und Dienstleistung

                                                                                                                     GmbH
                                                                                                                     und Co. KG
	 	E&K
    Data AG	 	Kanzenel
    & Beisenherz
	Bueromarkt
    Am Nordbahnhof GmbH	 	Edeka
    Zentralhandelsgesellsch Mbh (EA)	 	Karstadt
    Warenhaus GmbH DE
	Büroring
    EG	 	Electronic
    Partner Handel SE	 	Kaufhof
    Warenhaus AG.
	C
    & C Grossmarkt Balanstrasse	 	Elektronik
    Neumerkel GmbH	 	Keldenich
    & Weinberg GBR
	C
    & C Scharper GmbH	 	Ernst
    Binder GmbH & Co KG	 	Knoll
    Elektro Grosshandel GmbH & Co KG
	Cancom
    Deutschland GmbH	 	Euronics
    Deutschland eG	 	Komet
    Electronic GmbH
	Carl
    Mettler	 	EWS	 	KSK
    Elektro Handelsges mbH & Co KG
	CD
    Rohling up GmbH	 	Expert
    Warenvertriebs GmbH	 	Lyreco
    Deutschland GmbH

 

    	9/10

    	 

    

 

 

 

	MeCan
    Distribution GmbH & Co.KG	 	REWE
    Unterhaltungselektronik GmbH	 	 
	MEDIA
    MARKT TV-HiFi-Elektro GmbH	 	REWE
    Zentral AG	 	 
	MediaCom
    IT Distibution GmbH	 	Rexel
    Deutschland EFGH GmbH	 	 
	Media-Saturn
    Verwaltung Deutschland GmbH	 	Rimage
    Europe GmbH	 	 
	Medimax
    Electronic	 	Ringfoto
    GmbH & Co	 	 
	Metro
    Cash & Carry Deutschland GmbH	 	Saturn
    Techno Markt Handels GmbH	 	 
	Minipreis
    Laeden GmbH	 	SBK
    Selbstbed GmbH & Co KG	 	 
	Misco
    Germany Inc	 	Schimek
    Electronics Vertriebsgesellschaft MbH	 	 
	Mitegro
    GmbH & Co KG	 	Siemens
    AG	 	 
	Mueller
    Grosshandels Ltd. & Co. KG.	 	Sinus
    Gesellschaft f. EDV-Zubehoer mbH	 	 
	MÜLLER
    Ltd & Co KG	 	SK
    Kassetten GmbH & Co. KG	 	 
	Müller
    Service Ltd. & Co. KG	 	Soennecken
    LogServe GmbH	 	 
	Multi-Center
    Warenvertriebs GmbH	 	Soft
    Carrier Computerzubehoer GmbH	 	 
	Nierle
    Media GmbH & Co KGa	 	Software
    Partner GmbH	 	 
	Noesse
    Datentechnik GmbH	 	Spicers
    Deutschland GmbH	 	 
	NORMA
    GmbH & Co. KG	 	Spicers
    Ltd Deutschland	 	 
	Office
    Depot International B V	 	Staples
    (Deutschland) GmbH	 	 
	OHG
    Fegro Selgros	 	Ströbelt
    GmbH & Co	 	 
	Open
    Storage AG	 	TAROX
    Systems & Services GmbH	 	 
	Patz
    GmbH	 	TDK
    Electronics Europe GmbH	 	 
	Paul
    Opitz & Co GmbH	 	UFP
    Deutschland GmbH	 	 
	Photo
    Dose GmbH	 	Verbatim
    Limited	 	 
	PPI
    Trading	 	Walter
    Vigener GmbH & Co KG	 	 
	Pressezentrum
    Lübeck GmbH & Co KG	 	Wave
    Distribution & Computersysteme GmbH	 	 
	Printus
    Fachvertrieb für Bürobedarf GmbH	 	Wessling	 	 
	ProMarkt
    Handels GmbH	 	Wilhelm
    Koch GmbH	 	 
	Ratio
    Handel GmbH & Co KG	 	Wilhelm
    Rink GmbH & Co KG	 	 
	REAL
    SB-WARENHAUS GMBH	 	Wortmann
    AG	 	 
	Reichelt
    Elektronik GmbH & Co. KG	 	Zander
    GmbH & Co	 	 
	Relcom-Teh	 	 	 	 
	Rewe
    Grossfl. Mainz-Kastel Toom	 	 	 	 

 

    	10/10EX-4.1

 Exhibit 4.1 

Execution Version 

TCR2 THERAPEUTICS INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
	 1.
	  		  	Definitions	  	 	1	 
				
	 2.
	  		  	Registration Rights	  	 	4	 
				
		  	2.1	  	Demand Registration	  	 	4	 
		  	2.2	  	Company Registration	  	 	5	 
		  	2.3	  	Underwriting Requirements	  	 	6	 
		  	2.4	  	Obligations of the Company	  	 	7	 
		  	2.5	  	Furnish Information	  	 	9	 
		  	2.6	  	Expenses of Registration	  	 	9	 
		  	2.7	  	Delay of Registration	  	 	9	 
		  	2.8	  	Indemnification	  	 	9	 
		  	2.9	  	Reports Under Exchange Act	  	 	11	 
		  	2.10	  	Limitations on Subsequent Registration Rights	  	 	12	 
		  	2.11	  	“Market Stand-off” Agreement	  	 	12	 
		  	2.12	  	Restrictions on Transfer	  	 	13	 
		  	2.13	  	Termination of Registration Rights	  	 	14	 
				
	 3.
	  		  	Information and Observer Rights	  	 	15	 
				
		  	3.1	  	Delivery of Financial Statements	  	 	15	 
		  	3.2	  	Inspection	  	 	16	 
		  	3.3	  	Termination of Information Rights	  	 	16	 
		  	3.4	  	Confidentiality	  	 	16	 
				
	 4.
	  		  	Rights to Future Stock Issuances	  	 	17	 
				
		  	4.1	  	Right of First Offer	  	 	17	 
		  	4.2	  	Termination	  	 	18	 
				
	 5.
	  		  	Additional Covenants	  	 	18	 
				
		  	5.1	  	Insurance	  	 	18	 
		  	5.2	  	Employee Agreements	  	 	18	 
		  	5.3	  	Employee Stock	  	 	19	 
		  	5.4	  	Matters Requiring Preferred Director Approval	  	 	19	 
		  	5.5	  	Board Matters	  	 	20	 
		  	5.6	  	Successor Indemnification	  	 	20	 
		  	5.7	  	Termination of Covenants	  	 	20	 
				
	 6.
	  		  	Miscellaneous	  	 	20	 
				
		  	6.1	  	Successors and Assigns	  	 	20	 
		  	6.2	  	Governing Law	  	 	21	 
		  	6.3	  	Counterparts	  	 	21	 
		  	6.4	  	Titles and Subtitles	  	 	21	 
		  	6.5	  	Notices	  	 	21	 
		  	6.6	  	Amendments and Waivers	  	 	21	 

  
 i 

									
		  	 6.7
	  	 Severability
	  	 	22	 
		  	 6.8
	  	 Aggregation of Stock
	  	 	22	 
		  	 6.9
	  	 Additional Investors
	  	 	22	 
		  	 6.10
	  	 Entire Agreement
	  	 	22	 
		  	 6.11
	  	 Dispute Resolution
	  	 	22	 
		  	 6.12
	  	 Delays or Omissions
	  	 	24	 
		  	 6.13
	  	 Acknowledgment
	  	 	24	 

  

			
	Schedule A  	  	Schedule of Investors

  
 ii 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 28th day of February, 2018, by and among TCR2 Therapeutics Inc., a Delaware corporation (the “Company”), each of the investors listed
on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Series B Preferred Stock Purchase Agreement, dated as of the date hereof, by and among
the Company and certain of the Investors (the “Purchase Agreement”)) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 

RECITALS 
 WHEREAS,
certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred Stock, par value $0.0001 per shares (“Series A Preferred Stock”) and/or shares of the Company’s common
stock, par value $0.0001 per share (“Common Stock”) issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Investors’ Rights Agreement, dated
as of October 16, 2015, by and among the Company and such Investors (the “Prior Agreement”); 
 WHEREAS, the
Existing Investors are holders of a majority of the Registrable Securities (as defined in the Prior Agreement) then outstanding (the “Prior Requisite Holders”), and desire to amend and restate the Prior Agreement in its entirety and
to accept the rights created pursuant to this Agreement and the other Transaction Agreements (as such term is defined in the Purchase Agreement) in lieu of the rights granted to them under the Prior Agreement; and 

WHEREAS, certain of the Investors are parties to the Purchase Agreement, under which certain of the Company’s and such
Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, the Prior Requisite Holders, and the Company. 

NOW, THEREFORE, the Existing Investors and the Company hereby agree that the Prior Agreement shall be amended and restated, and the
parties to this Agreement further agree as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including without limitation any general partner, limited partner, member, manager, managing member, employee, officer or director of such Person or any venture capital fund now or
hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. As used herein, “control,” as used with respect to any Person, shall mean the
possession, directly or indirectly, of the power to direct the management or policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise, and the terms “controlling”
and “controlled” shall have meanings correlative to the foregoing. 

 1.2 “Competitor” means a Person engaged, directly or indirectly (including
through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the research and development of adoptive T-cell
therapies, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any Competitor and does not, nor do any of its
Affiliates, have a right to designate any members of the Board of Directors of any Competitor. 
 1.3 “Damages” means any
loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 
 1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in
each case, directly or indirectly), Common Stock, including options and warrants. 
 1.5 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6 “Excluded Registration” means
(i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.7 “Form
S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.8 “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.9 “GAAP” means generally accepted accounting principles in the United States. 

  
 2 

 1.10 “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.11 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships of a natural person referred to herein. 

1.12 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.13 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act. 

1.14 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.15 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.16 “Preferred Director” has the meaning set forth in the Company’s Certificate of Incorporation. 

1.17 “Preferred Stock” means, collectively, shares of Series A Preferred Stock and Series B Preferred Stock. 

1.18 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock
issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i)
and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for
purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.19 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.20 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in
Subsection 2.12(b) hereof. 
 1.21 “SEC” means the Securities and Exchange Commission. 

  
 3 

 1.22 “SEC Rule 144” means Rule 144 promulgated by the SEC under the
Securities Act. 
 1.23 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.24 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.25 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale
of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

1.26 “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding,
including at least a majority of the Common Stock issuable or issued upon conversion of the Series A Preferred Stock and at least a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock (the
“Requisite Holders”), that the Company file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then outstanding (or a lesser
percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $5 million), then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand
Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
Subsections 2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at any time when it
is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, 

  
 4 

 
file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by
any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3.

 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for
such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or
(iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, for a period of not more than sixty (60) days
after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than twice in any twelve (12) month period; and provided further that the Company shall not register any
securities for its own account or that of any other stockholder during such sixty (60) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a)
(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated
registration; provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to
Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made
pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty (30) days before the
Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration; provided that the Company is actively employing in good faith
commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately
preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC,
unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such
withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 
 2.2
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the
public offering of such 

  
 5 

 
securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given
within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be
included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to
include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by
the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this
Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of
Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, 

  
 6 

 
then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities
owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced
unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty percent (20%) of the
total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities
are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired
partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons,
shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such
“selling Holder,” as defined in this sentence. 
 (c) For purposes of Subsection 2.1, a registration shall not be
counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than thirty percent (30%) of the total number of Registrable Securities that Holders have requested
to be included in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities, including at least a majority of the Common Stock issuable or issued upon conversion of the Series A
Preferred Stock and at least a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock, registered thereunder, keep such registration statement effective for a period of up to one hundred twenty
(120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal
to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable
Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended
for up to sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

  
 7 

 (b) prepare and file with the SEC such amendments and supplements to such registration
statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling
Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

  
 8 

 In addition, the Company shall ensure that, at all times after any registration statement
covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent
to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to
exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration
proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities, including at least a majority of the Common Stock issuable or
issued upon conversion of the Series A Preferred Stock and at least a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock, to be registered (in which case all selling Holders shall bear such expenses pro
rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities, including at least a majority of the Common Stock issuable or issued upon
conversion of the Series A Preferred Stock and at least a majority of the Common Stock issuable or issued upon conversion of the Series B Preferred Stock, agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or
2.1(b), as the case may be. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining
or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from 

  
 9 

 
which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in
settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or
are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with
such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless
the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any
underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such
Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such
selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of
the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d)
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give
the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by
one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any
such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The
failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

  
 10 

 (d) To provide for just and equitable contribution to joint liability under the Securities
Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8
provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case,
such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the
indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material
fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided,
however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and
(y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided
further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the
offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:

 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for the IPO; 

  
 11 

 (b) use commercially reasonable efforts to file with the SEC in a timely manner all reports
and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the
Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to
Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the
selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the
Company so qualifies to use such form). 
 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Requisite Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such holder the right to include
securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of
Registrable Securities that they wish to so include; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without
the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under
the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such
period not to exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of
research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto),
(i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any
shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement or such offering, or (ii) enter into any
swap or other arrangement that transfers to another, in whole or in 

  
 12 

 
part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock
or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust
for the direct or indirect benefit of the Holder or the immediate family of the Holder; provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein; and provided further that any such
transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company obtains a similar agreement from all stockholders individually owning
more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third party
beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested
by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of
such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 13 

 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to
the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the
Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the
proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration
will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of
the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the
notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder
distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry
representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that
such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the
Securities Act. 
 2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of
Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s
shares without limitation during a three-month period without registration; and 

  
 14 

 (c) the fifth anniversary of a Qualified Public Offering, as such term is defined in the
Company’s Certificate of Incorporation. 
 3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Investor, provided that the Board of Directors has not
reasonably determined that such Investor is a Competitor: 
 (a) as soon as practicable, but in any event within ninety (90) days after
the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year; 

(b) as soon as practicable, but in any event within forty five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements
may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock
issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet
issued but reserved for issuance, if any, all in sufficient detail as to permit the Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the
Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event thirty (30) days before the end of each
fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised
budgets prepared by the Company; 
 (e) as soon as practicable, but in any event within thirty (30) days of the Company’s receipt
of a written appraisal of the Common Stock from an independent valuation firm for purposes of compliance with Section 409A of the Internal Revenue Code, a copy of such valuation; and 

(f) such other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Investor may
from time to time reasonably request; provided, however, that the Company shall not be obligated under this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret
or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its
counsel. 

  
 15 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in
this Subsection 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the
SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its
commercially reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit
each Investor (provided that the Board of Directors has not reasonably determined that such Investor is a Competitor), at such Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and
records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Investor; provided, however, that the Company shall not be
obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in
form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information Rights. The covenants set forth in Subsections 3.1 and 3.2 shall terminate and be of
no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a
Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 3.4
Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the
Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a
result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known
or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys,
accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective 

  
 16 

 
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.4; (iii) to any Affiliate,
partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business; provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the
confidentiality of such information; or (iv) as may otherwise be required by law; provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required
disclosure. 
 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems
appropriate, among (i) itself and (ii) its Affiliates; provided that each such Affiliate (x) is not a Competitor, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, and
(y) agrees to enter into this Agreement and each of the Amended and Restated Voting Agreement and Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company,
the Investors and the other parties named therein, as an “Investor” under each such agreement. 
 (a) The Company shall
give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon
which it proposes to offer such New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is
given, each Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor
(including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of
the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor
that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given
such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to
subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other
Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative
Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of one hundred and twenty (120) days of
the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

  
 17 

 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased
or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of
such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities
within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the
Investors in accordance with this Subsection 4.1. 
 (d) The right of first offer in this Subsection 4.1 shall not
be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series B Preferred Stock to Additional
Purchasers. 
 4.2 Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no further force or
effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation
Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 5. Additional
Covenants. 
 5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain, within ninety (90) days of
the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance and term “key person” insurance on Patrick Baeuerle, each in an amount and on terms and conditions satisfactory to the Board of
Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. The key person policy shall name the Company
as loss payee, and neither policy shall be cancelable by the Company without prior approval by the Board of Directors, including all of the Series A Directors. 

5.2 Employee Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or engaged by the
Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and a one (1) year noncompetition and
nonsolicitation agreement, substantially in (i) the form previously approved by the Board of Director and made available to the Investors or (ii) a form approved after the date hereof by the Board of Directors, including a majority of the
Preferred Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without
the consent of the Board of Directors, including a majority of the Preferred Directors. 

  
 18 

 5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including a
majority of the Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute
restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued
employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off
provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the Board of Directors, including a majority of the Preferred Directors, the Company shall retain a “right of first refusal”
on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Matters Requiring Preferred Director Approval. So long as the holders of Series A Preferred Stock and/or Series B Preferred Stock
are entitled to elect one or more Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of a majority
of the Preferred Directors: 
 (a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of,
any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (b) make, or permit any
subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an
employee stock or option plan approved by the Board of Directors; 
 (c) guarantee, directly or indirectly, or permit any subsidiary to
guarantee, directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 

(d) implement or change a cash investment policy, and make any investment inconsistent with any investment policy approved by the Board of
Directors; 
 (e) incur any aggregate indebtedness or make any aggregate expenditures in excess of 2% of the aggregate expenditure amount
set forth in the budget for a given fiscal year approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f) hire, terminate, or change the compensation of the executive officers, or approve or amend any stock option or equity incentive plans;

  
 19 

 (g) change the principal business of the Company, enter new lines of business, or exit the
current line of business; or 
 (h) sell, assign, license, pledge, or encumber material technology or intellectual property, other than
licenses granted in the ordinary course of business. 
 5.5 Board Matters. The Company shall reimburse the nonemployee directors for
all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors
and other meetings or events attended on behalf of the Company or at the Company’s request. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an audit and compensation committee, each of
which shall consist solely of non-management directors. Each non-employee director shall be entitled in such person’s discretion to be a member of any Board
committee; for clarity, each Preferred Director will have the right to serve on any such committee. 
 5.6 Successor Indemnification.
If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are
contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 5.7 Termination of
Covenants. The covenants set forth in this Section 5, except for Subsection 5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company
first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever
event occurs first. 
 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds at least 200,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the
Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee
agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of
Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s 

  
 20 

 
Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the
transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for
the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the
parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of
this Agreement, except as expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by the internal law of the
State of Delaware. 
 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested,
postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in
the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy (which shall not
constitute notice) shall also be sent to Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attention: Mitchell S. Bloom, Esq. and William D. Collins, Esq. 

6.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders; provided that the Company may in its sole discretion waive compliance with
Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided
further that any provision hereof may be waived by any 

  
 21 

 
waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any
term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the
Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any
amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or
provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. Notwithstanding the foregoing, Schedule A hereto may be amended by the
Company from time to time in accordance with Sections 6.9 to add information regarding additional Investors without the consent of the other parties hereto. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall
be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be
bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement. This Agreement (including any
Schedules hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is
expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

  
 22 

 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of Massachusetts and to the jurisdiction of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this
Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Massachusetts or the United States District Court for the District of Massachusetts, and
(c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be
enforced in or by such court. 
 Any unresolved controversy or claim arising out of or relating to this Agreement, except as
(i) otherwise provided in this Agreement, or (ii) any such controversies or claims arising out of either party’s intellectual property rights for which a provisional remedy or equitable relief is sought, shall be submitted to
arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the
“AAA”), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in Massachusetts, in accordance
with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows:
(a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c) such other depositions as may be allowed by the
arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the Massachusetts Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such
arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. 

Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to
reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the
U.S. District Court for the District of Massachusetts or any court of the Commonwealth of Massachusetts having subject matter jurisdiction. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL 

  
 23 

 
NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No delay or omission
to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor
shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review
the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any
way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. In addition, the Company hereby agrees and acknowledges that
each of the Investors and certain of their Affiliates are professional venture capital investment funds (collectively, the “Funds”), and as such invest in numerous portfolio companies, some of which may be deemed competitive with
the Company’s business (as currently conducted or as may be conducted in the future). The parties agree that no Fund or any Affiliate of a Fund that is an investment fund, or any of their Affiliates or any of their or their Affiliates’
partners, officers or representatives which manage or advise any such investment funds shall be considered a Competitor of the Company as a result of such investment, management or advisory activities for purposes of this Agreement (including for
purposes of Sections 1.3, 3.1, 3.2 and 4.1 hereof) and the Company agrees that, to the extent permitted under applicable law, neither the Funds nor their Affiliates shall be liable to the Company for any claim arising out
of, or based upon, (i) the investment by a Fund or any of its Affiliates in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of a Fund or its Affiliates to assist any such
competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing
shall not relieve (x) any of the Funds from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any
liability associated with his or her fiduciary duties to the Company. 
 [Signature Pages Follow] 

 

  
 24 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	 COMPANY:

	
	 TCR2 THERAPEUTICS
INC.

		
	 By:
	 	 /s/ Garry Menzel

		 	 Name: Garry Menzel

		 	 Title: President and Chief Executive Officer

		
		 	 Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	 INVESTOR:

	
	 CURATIVE VENTURES

		
	 By:
	 	 /s/ Bronson Crouch

	 Name:
	 	 Bronson Crouch

	 Title:
	 	 Managing Member

	
	 Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	 INVESTOR:

	
	 6 DIMENSIONS CAPITAL,
L.P.

 
			
	 By: 6 Dimensions GP, LLC, its General
Partner

 
			
		
	 By:
	 	 /s/ Wei Li

 
			
	 Name:
	 	 Wei Li

			
	 Title:
	 	 Director

			
	
	 Date: March 5, 2018

	
	6 DIMENSIONS AFFILIATES FUND, L.P.
	
By: 6 Dimensions Capital GP, LLC, its General 
Partner

 
			
		
	 By:
	 	 /s/ Wei Li

 
			
	 Name:
	 	 Wei Li

	 Title:
	 	 Director

	
	 Date: March 5, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	MPM BIOVENTURES 2014, L.P.
	
	By: MPM BIOVENTURES 2014 GP LLC, its general partner
	
	By: MPM BIOVENTURES 2014 LLC, its managing member
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Managing Director
	
	Date: February 28, 2018
	
	MPM BIOVENTURES 2014 (B), L.P.
	
	By: MPM BIOVENTURES 2014 GP LLC, its general partner
	
	By: MPM BIOVENTURES 2014 LLC, its managing member
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Managing Director
	
	Date: February 28, 2018
	
	MPM ASSET MANAGEMENT INVESTORS BV2014 LLC
	
	By: MPM BIOVENTURES 2014 LLC, its manager
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Managing Director
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	MPM SUNSTATES FUND, L.P.
	
	By: MPM SUNSTATES FUND GP LLC, its general partner
	
	By: MPM SUNSTATES GP MANAGING MEMBER LLC, its managing member
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Member
	
	Date: February 28, 2018
	
	MPM ASSET MANAGEMENT INVESTORS SUNSTATES FUND LLC
	
	By: MPM SUNSTATES GP MANAGING MEMBER LLC, its Manager
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Member
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	UBS ONCOLOGY IMPACT FUND, L.P.
	
	By: ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P., its general partner
	By: MPM ONCOLOGY IMPACT MANAGEMENT LP, its general partner
	By: MPM ONCOLOGY IMPACT MANAGEMENT GP LLC, its general partner
		
	By:	 	 /s/ Ansbert Gadicke

	Name:	 	Ansbert Gadicke
	Title:	 	Managing Director
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	F2 CAPITAL I 2015 LIMITED
		
	By:	 	 /s/ Vanessa Briceno

	Name:	 	Vanessa Briceno
	Title:	 	Director, Cellar Limited
	
	Date: February 28, 2018
		
	By:	 	 /s/ Ross Belhomme

	Name:	 	Ross Belhomme
	Title:	 	Director, Clambake Limited
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	F2 CAPITAL I 2017 LIMITED
		
	By:	 	 /s/ Vanessa Briceno

	Name:	 	Vanessa Briceno
	Title:	 	Director, Cellar Limited
	
	Date: February 28, 2018
		
	By:	 	 /s/ Ross Belhomme

	Name:	 	Ross Belhomme
	Title:	 	Director, Clambake Limited
	
	Date: February 28, 2018
	
	F2-TPO INVESTMENTS, LLC
		
	By:	 	 /s/ Vanessa Briceno

	Name:	 	Vanessa Briceno
	Title:	 	Director, Cellar Limited
	
	Date: February 28, 2018
		
	By:	 	 /s/ Ross Belhomme

	Name:	 	Ross Belhomme
	Title:	 	Director, Clambake Limited
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	F2 BIOSCIENCE II 2017 LIMITED
		
	By:	 	 /s/ Vanessa Briceno

	Name:	 	Vanessa Briceno
	Title:	 	Director, Cellar Limited
	
	Date: February 28, 2018
		
	By:	 	 /s/ Ross Belhomme

	Name:	 	Ross Belhomme
	Title:	 	Director, Clambake Limited
	
	Date: February 28, 2018
	
	F2 MG LIMITED
		
	By:	 	 /s/ Vanessa Briceno

	Name:	 	Vanessa Briceno
	Title:	 	Director, Cellar Limited
	
	Date: February 28, 2018
		
	By:	 	 /s/ Ross Belhomme

	Name:	 	Ross Belhomme
	Title:	 	Director, Clambake Limited
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	UPNORTH INVESTMENT LIMITED
		
	By:	 	 /s/ Li Chaochun

	Name:	 	Li Chaochun
	Title:	 	Director
	
	Date: March 5, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	MIRAE ASSET-CELLTRION NEW GROWTH FUND I
	By: MiraeAsset Capital co., Ltd, its general partner
		
	By:	 	 /s/ KuBeom LEE

	Name:	 	KuBeom LEE
	Title:	 	CEO of MiraeAsset Capital co., Ltd.
	
	Date: March 19, 2018
	
	MIRAE ASSET YOUNG START-UP
	INVESTMENT FUND #2
	By: MIRAE ASSET Venture Investment,
	Co, Ltd., its general partner
		
	By:	 	 /s/ Eung Suk KIM

	Name:	 	Eung Suk KIM
	Title: CEO of MIRAE ASSET Venture
	Investment, Co, Ltd
	
	Date: March 15, 2018
	
	MIRAE ASSET VENTURE INVESTMENT, CO, LTD.
		
	By:	 	 /s/ Eung Suk KIM

	Name:	 	Eung Suk KIM
	Title:	 	CEO of MIRAE ASSET Venture
	Investment, Co, Ltd
	
	Date: March 15, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	LEERINK HOLDINGS LLC
		
	By:	 	 /s/ Joseph R. Gentile

		 	Name: Joseph R. Gentile
		 	Title: CAO
	
	Date: February 28, 2018
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
		
	By:	 	 /s/ Joseph R. Gentile

		 	Name: Joseph R. Gentile
		 	Title: Manager
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	 THE SANGREAL TRUST, DATED

DECEMBER 1, 2009

		
	By:	 	 /s/ Brian Sheth

	Name: Brian Sheth
	Title: Trustee
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
		
	By:	 	 /s/ Stephen Turkowiak

	Stephen Turkowiak
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTOR:
	
	 ALEXANDRIA VENTURE INVESTMENTS, LLC,

a Delaware limited liability company

	
	By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member
		
	By:	 	 /s/ Aaron Jacobson

		 	Name: Aaron Jacobson
		 	Title: VP – Corporate Counsel
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	SYNO VENTURES MASTER FUND, LP
		
	By:	 	 /s/ Justin Xiang

		 	Name: Justin Xiang
		 	Title: General Partner
	
	Date: March 14, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	SYNO HAITONG INTERNATIONAL TCR, LLC
		
	By:	 	 /s/ Justin Xiang

		 	Name: Justin Xiang
		 	Title: Managing Member
	
	Date: March 14, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	MERIDIAN SMALL CAP GROWTH FUND
	By: its Investment Adviser
	ArrowMark Colorado Holdings, LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018
	
	ARROWMARK FUNDAMENTAL
	OPPORTUNITY FUND, L.P.
	By: its General Partner
	ArrowMark Partners GP, LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018
	
	LOOKFAR INVESTMENTS LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	CF ASCENT LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018
	
	THB IRON ROSE LLC
	By: its Investment Adviser
	ArrowMark Colorado Holdings, LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018
	
	THB IRON ROSE LLC, LIFE SCIENCE
	PORTFOLIO
	By: its Investment Adviser
	ArrowMark Colorado Holdings, LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	Tony Yao
		
	By:	 	 /s/ Tony Yao

		 	Name: Tony Yao
	
	Date: February 28, 2018
	
	IRON HORSE INVESTMENTS LLC
	By: its Investment Adviser
	ArrowMark Colorado Holdings, LLC
		
	By:	 	 /s/ David Corkins

		 	Name: David Corkins
		 	Title: Managing Member
	
	Date: February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	REDMILE CAPITAL FUND, LP
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the General Partner and the Investment Manager
	
	Date: March 5, 2018
	
	REDMILE CAPITAL OFFSHORE FUND, LTD.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the Investment Manager
	
	Date: March 5, 2018
	
	REDMILE CAPITAL OFFSHORE FUND II, LTD.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the Investment Manager
	
	Date: March 5, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

			
	INVESTORS:
	
	REDMILE BIOPHARMA INVESTMENTS I, L.P.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the Management Company / General Partner
	
	Date: March 5, 2018
	
	RAF, L.P.
		
	By:	 	 /s/ Jeremy Green

	Name:	 	Jeremy Green
	Title:	 	Managing Member of the General Partner and the Management Company
	
	Date: March 5, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

					
	PRECISION ONCO LIMITED
		
	By:	 	 /s/ Yuan Sun

		 	Name:	 	Yuan Sun
		 	Title: Director
	
	Date: March 21, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

					
	HH TCRII HOLDINGS LIMITED
		
	By:	 	 /s/ Colm O’Connell

		 	Name:	 	Colm O’Connell
		 	Title: Director
	
	Date: March 9, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

					
	DRAGON RIDER LIMITED
		
	By:	 	 /s/ Biao Wang

		 	Name: Biao Wang
		 	Title: President, Lucion Venture Capital Group Co., Ltd.
	
	Date:  February 28, 2018

  
 [Signature Page to
Amended and Restated Investors’ Rights Agreement] 

 SCHEDULE A 

INVESTORS 
 Name and Address

 Curative Ventures 
 5949 Sherry Lane 

Suite 820 
 Dallas, TX 75225 

Attn: Bronson Crouch 
 The Sangreal Trust, Dated December 1,
2009 
 3502 Sacred Moon Cove 
 Austin, TX 78746 

Attn: Andy Geller 
 ageller@westernpeakia.com 

MPM BioVentures 2014, L.P. 
 MPM BioVentures 2014 (B), L.P. 

MPM Asset Management Investors BV2014 LLC 
 c/o MPM Capital LLC

 450 Kendall Street 
 Cambridge, MA 02142 

Attn: Sarah Reed 
 Phone: 617-425-9205 
 Fax: 617-425-9201

 Email: sreed@MPMCapital.com 
 MPM Sunstates Fund, L.P. 

MPM Asset Management Investors Sunstates Fund LLC 
 c/o MPM
Capital LLC 
 450 Kendall Street 
 Cambridge, MA 02142 

Attn: Sarah Reed 
 Phone: 617-425-9205 
 Fax: 617-425-9201

 Email: sreed@MPMCapital.com 

 F2 Capital I 2015 Limited 

Attn: c/o Charles Mia 
 Phone: +44 2075295848 

Fax: +442075295849 
 Email: edward.cain@charlesmia.com 

Mailing address: 
 c/o LJ Skye 

Rue du Seyon 2 
 CP 2048 

2001 Neuchatel 
 Switzerland 

Attention: Vanessa Briceno 
 F2 Capital I 2017 Limited 

Attn: c/o Charles Mia 
 Phone: +44 2075295848 

Fax: +442075295849 
 Email: edward.cain@charlesmia.com 

Mailing address: 
 c/o LJ Skye 

Rue du Seyon 2 
 CP 2048 

2001 Neuchatel 
 Switzerland 

Attention: Vanessa Briceno 

F2-TPO Investments, LLC 

Attn: c/o Charles Mia 
 Phone: +44 2075295848 

Fax: +442075295849 
 Email: edward.cain@charlesmia.com 

Mailing address: 
 c/o LJ Skye 

Rue du Seyon 2 
 CP 2048 

2001 Neuchatel 
 Switzerland 

Attention: Vanessa Briceno 
 F2 Bioscience II 2017 Limited 

Attn: c/o Charles Mia 
 Phone: +44 2075295848 

Fax: +442075295849 
 Email: edward.cain@charlesmia.com 

Mailing address: 
 c/o LJ Skye 

Rue du Seyon 2 
 CP 2048 

2001 Neuchatel 
 Switzerland 

Attention: Vanessa Briceno 

 F2 MG Limited 

Attn: c/o Charles Mia 
 Phone: +44 2075295848 

Fax: +442075295849 
 Email: edward.cain@charlesmia.com 

Mailing address: 
 c/o LJ Skye 

Rue du Seyon 2 
 CP 2048 

2001 Neuchatel 
 Switzerland 

Attention: Vanessa Briceno 
 UBS Oncology Impact Fund L.P. 

MUFG Alternative Fund Services (Jersey) Limited 
 Durell House

 28 New Street 
 St Helier 

Jersey 
 JE1 4FS 

Meridian Small Cap Growth Fund 
 ArrowMark Partners 

100 Fillmore Street, Suite 325 
 Denver, CO 80206 

Telephone: 303-398-2950 

Email: rgrove@arrowmarkpartners.com 
 Attn: Rick Grove 

ArrowMark Fundamental Opportunity Fund, L.P. 
 ArrowMark Partners

 100 Fillmore Street, Suite 325 
 Denver, CO 80206 

Telephone: 303-398-2950 

Email: rgrove@arrowmarkpartners.com 
 Attn: Rick Grove 

Lookfar Investments LLC 
 ArrowMark Partners 

100 Fillmore Street, Suite 325 
 Denver, CO 80206 

Telephone: 303-398-2950 

Email: rgrove@arrowmarkpartners.com 
 Attn: Rick Grove 

 CF Ascent LLC 

ArrowMark Partners 
 100 Fillmore Street, Suite 325 

Denver, CO 80206 
 Telephone: 303-398-2950 
 Email: rgrove@arrowmarkpartners.com 

Attn: Rick Grove 
 THB Iron Rose LLC 

ArrowMark Partners 
 100 Fillmore Street, Suite 325 

Denver, CO 80206 
 Telephone: 303-398-2950 
 Email: rgrove@arrowmarkpartners.com 

Attn: Rick Grove 
 THB Iron Rose LLC, Life Science Portfolio 

ArrowMark Partners 
 100 Fillmore Street, Suite 325 

Denver, CO 80206 
 Telephone: 303-398-2950 
 Email: rgrove@arrowmarkpartners.com 

Attn: Rick Grove 
 Tony Yao 

ArrowMark Partners 
 100 Fillmore Street, Suite 325 

Denver, CO 80206 
 Telephone: 303-398-2950 
 Email: rgrove@arrowmarkpartners.com 

Attn: Rick Grove 
 Iron Horse Investments LLC 

ArrowMark Partners 
 100 Fillmore Street, Suite 325 

Denver, CO 80206 
 Telephone: 303-398-2950 
 Email: rgrove@arrowmarkpartners.com 

Attn: Rick Grove 
 Leerink Holdings LLC 

One Federal Street, 37th Floor 
 Boston, MA 02110 

Attention: General Counsel 
 Leerink Swann Co-Investment Fund, LLC 
 One Federal Street, 37th Floor 

Boston, MA 02110 
 Attention: General Counsel 

 Alexandria Venture Investments, LLC 

385 E. Colorado Blvd., Suite 299 
 Pasadena, CA
91101     
 Stephen Turkowiak 
 566 Trapelo
Rd. 
 Belmont, MA 02478 
 Phone:
858-735-5396 
 Email: Stephen.turkowiak@tcr2.com 

6 Dimensions Capital, L.P. 
 55 Cambridge Parkway, 8th Floor 

Cambridge MA 02142 
 Attn: Wei Li 

Tel: 617.374.1610 
 Fax: 617.374.1623 

wei.li@6dimensionscapital.com 
 6 Dimensions Capital Affiliates
Fund, L.P. 
 55 Cambridge Parkway, 8th Floor 
 Cambridge MA
02142 
 Attn: Wei Li 
 Tel: 617.374.1610 

Fax: 617.374.1623 
 wei.li@6dimensionscapital.com 

UpNorth Investment Limited 
 52F, International Financial Centre
(IFC) II, 8 Century Avenue, Pudong District 
 Shanghai, 200120, China 

Recipient: Chen Li     
 Direct: (+86) 21 6086
2163 
 Redmile Capital Fund, LP 
 c/o Redmile Group, LLC 

One Letterman Drive 
 Building D Suite D3-300 
 San Francisco, CA 94129 

Telephone: 415-489-9980 

Email: operations@redmilegrp.com 
 Attn: Josh Garcia 

Redmile Capital Offshore Fund, Ltd. 
 c/o Redmile Group, LLC 

One Letterman Drive 
 Building D Suite D3-300 
 San Francisco, CA 94129 

Telephone: 415-489-9980 

Email: operations@redmilegrp.com 
 Attn: Josh Garcia 

 Redmile Capital Offshore Fund II, Ltd. 

c/o Redmile Group, LLC 
 One Letterman Drive 

Building D Suite D3-300 

San Francisco, CA 94129 
 Telephone: 415-489-9980 
 Email: operations@redmilegrp.com 

Attn: Josh Garcia 
 Redmile Biopharma Investments I, L.P. 

c/o Redmile Group, LLC 
 One Letterman Drive 

Building D Suite D3-300 

San Francisco, CA 94129 
 Telephone: 415-489-9980 
 Email: operations@redmilegrp.com 

Attn: Josh Garcia 
 RAF, L.P. 

c/o Redmile Group, LLC 
 One Letterman Drive 

Building D Suite D3-300 

San Francisco, CA 94129 
 Telephone: 415-489-9980 
 Email: operations@redmilegrp.com 

Attn: Josh Garcia 
 Syno Ventures Master Fund, LP 

275 Madison Ave, 39th Floor 
 New York, NY 10016 

Telephone: 646-723-1915 

Attn: Justin Xiang 
 Syno Haitong International TCR, LLC 

275 Madison Ave, 39th Floor 
 New York, NY 10016 

Telephone: 646-723-1915 

Attn: Justin Xiang 
 HH TCRII HoldingsLimited 

Suite 1608 
 One Exchange Square 

8 Connaught Place 
 Central, Hong Kong 

Attn: Adam Hornung (General Counsel) 
 Email:
legal@hillhousecap.com 

 Dragon Rider Limited 

4F Block C, Times Plaza, No. 9999 
 Jingshi Road, Jinan,
Shandong, 250101, China 
 Attention: Biao Wang 
 Precision Onco
Limited 
 3rd floor, J & C Building, P.O. Box 933 

Road Town, Tortola, British Virgin Islands 
 Attn: Yuan Sun 

Mirae Asset Young Start-up Investment Fund #2 

(Glass Tower) 21F, 534, 

Teheran-ro Gangnam-gu, 

Seoul, 06181, Korea 
 Attn: Gil Tae, Wie 

Email: gtwie@miraeasset.com 
 Phone: +82-2-6205-2651 
 Fax: +82-2-6205-2680 
 Mirae Asset Venture Investment, Co, Ltd. 

(Glass Tower) 21F, 534, 

Teheran-ro Gangnam-gu, 

Seoul, 06181, Korea 
 Attn: Gil Tae, Wie 

Email: gtwie@miraeasset.com 
 Phone: +82-2-6205-2651 
 Fax: +82-2-6205-2680 
 Mirae Asset-Celltrion New Growth Fund I 

MiraeAsset Capital Co., Ltd 
 (MiraeAsset CENTER1 Bldg) 36F,
East-Tower, 26, Eulji-ro 5-gil, Jung-gu, Seoul, Korea. 04539 

Attn: SungWon Song 
 Email: sungwon.song@miraeasset.com 

Phone: +82-10-9583-9728 

Fax: +82-203774-5949

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00290-of-00352.parquet"}]]